PDCD1 and cancer: Enhanced antigen binding affinity of GNUV201 at low pH suggest the possibility that GNUV201 retains more favorable binding characteristics at low pH of the TME compared to other anti-PD-1 antibodies, which could lead to improved anti-cancer efficacy in terms of longer duration of efficacy or requiring less amount of dosing (Fig. S1).